SoilLifeSTART-UP PROPOSAL

Overview Vision Mission Key Product Business Plan (5 years term Goals) Intellectual Property and Patent Drug Development Plan Financial Plan Marketing Plant (Unique selling Points) Team and Company Structure

“

”

To discover and develop new drugs from soil that could be able to treat infections especially caused by multi-resistant pathogens .

Vision

“

”

To bioprospect soil in biodiversity hot spots for the purpose of finding a drug against resistant bacteria as MRSA, Streptoccocus and multiresistant Acinetobacter baumannii.

Mission

Key Product

Our Key Product ”Anneclymycin” is natural product that showed strong antibiotic action against multi resistant Acinetobacter baumannii, a gram negative bacteria which is responsible for difficult to treat wound infection in hospitals

The natural product was originally extracted from professor Nageli’s (Brazil Samples 1991) collected from Brazilian Atlantic Forest and East Island.

Business Plan

Five-years goals :

1. Launch our first product Anneclmycin to the market2. Start clinical trails for another 5 promising antibiotics originiated from soil bioprospecting in Brazil3. Acquisition of 20% of multidrug resistant Acinetobacter baumannii treament market share.

Intellectual Property and License Start Patent application Based on Convention of Biological diversity treaty 1992

and its supplementary agreement Nagoya protocol 2010,

we are planning to reach an agreement with BioAmazonia semi-governmental organization was set up by Brazilian government in order to manage the country's natural genetic resources.

Agreement will allow SoilLife to practice bioprospecting activities in Brazilian Atlantic Forest and Easter Island in compensation to 5 million dollars and 5% sharing of each discovered drug gets to a commercialized product (4% to Bioamazonia and 1% to indigenous people)

Drug Development PlanPromising Data

Investigational drug application

In vivo profiling

Safety studies

Proof of concept trial

New Drug Application

Market Penetration

Financial PlanYear4 Year3 Year2 Year 1

Proof of concept trial

Safety StudiesGMP

Production

In Vivo Profiling and

Production Up scaling

In Vitro profiling and

product optimization

Product development

stage

5 million dollars

Compensation for

Bioamazonia

6 Million Dollars

5 Million dollars

3 Million Dollars

1 Million dollars

External Development

Cost

5 Million Dollars

4.5 Million Dollars

3 Million Dollars

1.5 Million Dollars

Employee cost including

lab Cost

11 Million Dollars

9.5 Million dollars

6 Million Dollars

7.5 Million Dollars

Total

Financial PlanAnticipated

Market ShareCurrent

Market ShareTreatment

Course Cost

25% 0% 800 $ Anneclymycin

30% 40% 1000$ Sulbactam

30% 40% 900$ Carbapenem

15% 20% 2000$ Combination therapy

Financial Plan

At First Four years, Venture Capitalists will invest 34 million dollars before our first product Anneclymycin go to the market.

In Case of failure of investment, merging or acquisition by out-liscencing to another pharmaceutical company.

Marketing Plan

Unique Selling Points

1. Price 2. Single therapy and better patient adherence

The Team CEO

Ann Lee (PhD in molecular biology, PhD thesis about the genome comparison of Acinetobacter baumannii resistant strains.

Vice President Prof. Weiss from ETH Zurich (Supervisor of Ann’s Project )

Vice president Prof. Nageli ( 20 years expereince in natural products and the original author of Brazil Collection)

R&D Manager Dr. Wong(Former Screening department manager at Ninox Pharmaceuticals Basel, Collabotaor of Ann’s Project)

The Team and Company Structure

[Ann Lee ] President,

CEO

[Prof. Weiss ] Vice

President

[TBH] Manager

[TBH] Manager

[Prof. Nageli] Vice

President

[Dr. Wong] R&D

Manager

[TBH] Manager